MEDICAL TREATMENT IMPLEMENTATION IN AMBULATORY PATIENTS WITH HF: PRELIMINARY DATA FROM THE NATIONWIDE BRING-UP3 HF STUDY
Anno:
2025
Background: Current ESC guidelines introduced a four-pillar approach for the treatment of HFrEF, and a Class IA recommendation for Empagliflozin and Dapagliflozin in HFmrEF and HFpEF. Objectives: BRING-UP-3 Heart Failure (HF) study was designed to guide the Guideline implementation recommendations in HF patients enrolled by a large sample of…